MannKind CorporationViés de alta
MNKD
Trend continuation, possible bullish outlook as long as price can stay above channel.
MNKD (with partner Sanofi) is about to market and distribute FDA approved Afrezza, a inhaled insulin that can make insulin syringes a thing of the past. With diabetes a global condition that effects 371 million people worldwide and is expected to affect 552 million by 2030, MNKD is the only FDA approved product of this kind.
MNKD (with partner Sanofi) is about to market and distribute FDA approved Afrezza, a inhaled insulin that can make insulin syringes a thing of the past. With diabetes a global condition that effects 371 million people worldwide and is expected to affect 552 million by 2030, MNKD is the only FDA approved product of this kind.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.